Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1971 Jan;3(1):116–120. doi: 10.1128/iai.3.1.116-120.1971

Relationship Between the Staining Quality of Mycobacterium leprae and Infectivity for Mice

Dorothy H McRae 1, Charles C Shepard 1
PMCID: PMC416115  PMID: 16557926

Abstract

The proposal has been made that only solidly staining forms of Mycobacterium leprae are viable. On the basis of a previous study, solidly staining bacilli were defined as those that stained completely and darkly throughout their length. A study was carried out to correlate the proportion of solidly staining bacilli in inocula with the infectivity and rate of appearance of bacillary growth in inoculated mice. The inocula originated in skin biopsy specimens of patients and in mouse passage material; there were 347 inocula suitable for study. The rate of appearance of bacillary growth in inoculated mice confirmed the hypothesis that nonsolid bacilli are inert and nonviable and that all growth originates from the solidly staining organisms. The minimal infectious dose was determined in four suspensions and was found to range from 40 to 3 solidly staining bacilli.

Full text

PDF
116

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang Y. T., Andersen R. N. Morphological changes of Mycobacterium lepraemurium grown in cultures of mouse peritoneal macrophages. J Bacteriol. 1969 Sep;99(3):867–875. doi: 10.1128/jb.99.3.867-875.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. REES R. J., VALENTINE R. C. The appearance of dead leprosy bacilli by light and electron microscopy. Int J Lepr. 1962 Jan-Mar;30:1–9. [PubMed] [Google Scholar]
  3. Rees R. J. New prospects for the study of leprosy in the laboratory. Bull World Health Organ. 1969;40(5):785–800. [PMC free article] [PubMed] [Google Scholar]
  4. Rees R. J., Pearson J. M., Waters M. F. Experimental and clinical studies on rifampicin in treatment of leprosy. Br Med J. 1970 Jan 10;1(5688):89–92. doi: 10.1136/bmj.1.5688.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. SHEPARD C. C., MCRAE D. H. MYCOBACTERIUM LEPRAE IN MICE: MINIMAL INFECTIOUS DOSE, RELATIONSHIP BETWEEN STAINING QUALITY AND INFECTIVITY, AND EFFECT OF CORTISONE. J Bacteriol. 1965 Feb;89:365–372. doi: 10.1128/jb.89.2.365-372.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. SHEPARD C. C. Multiplication of Mycobacterium leprae in the foot-pad of the mouse. Int J Lepr. 1962 Jul-Sep;30:291–306. [PubMed] [Google Scholar]
  7. Shepard C. C., Congdon C. C. Increased growth of Mycobacterium leprae in thymectomized-irradiated mice after foot pad inoculation. Int J Lepr Other Mycobact Dis. 1968 Apr-Jun;36(2):224–227. [PubMed] [Google Scholar]
  8. Shepard C. C., Levy L., Fasal P. The death of Mycobacterium leprae during treatment with 4,4'-diaminodiphenylsulfone (DDS). Initial rate in patients. Am J Trop Med Hyg. 1968 Sep;17(5):769–775. doi: 10.4269/ajtmh.1968.17.769. [DOI] [PubMed] [Google Scholar]
  9. Shepard C. C., McRae D. H. A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis. 1968 Jan-Mar;36(1):78–82. [PubMed] [Google Scholar]
  10. Shepard C. C., McRae D. H. Hereditary Characteristic that Varies Among Isolates of Mycobacterium leprae. Infect Immun. 1971 Jan;3(1):121–126. doi: 10.1128/iai.3.1.121-126.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. WATERS M. F., REES R. J. Changes in the morphology of Mycobacterium leprae in patients under treatment. Int J Lepr. 1962 Jul-Sep;30:266–277. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES